Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 9:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Upper Extremity Impairments Clear all
Terminated Not applicable Interventional Results available

Brain Stimulation and Rehabilitation for Adults With Chronic, Severe Arm Motor Impairment After Stroke

NCT03538795
View directory record Official record
Conditions
Stroke, Hemiplegia, Hemiparesis
Interventions
iTBS&eCIMT
Combination Product
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03481634
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Brolucizumab, Aflibercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Results available

Effect of Cenicriviroc on HIV Neurocognitive Impairment

NCT02128828
View directory record Official record
Conditions
AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex, Human Immunodeficiency Virus
Interventions
cenicriviroc
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

NCT05108922
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Disease
Interventions
Donanemab, Aducanumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 85 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Fullerton, California • Irvine, California • Sherman Oaks, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 11, 2026, 9:11 AM EDT
Not listed Phase 1Phase 2 Interventional

Robotic Brace Incorporating Electromyography (EMG) for Moderate Affected Arm Impairment After Stroke

NCT01322997
View directory record Official record
Conditions
Stroke
Interventions
Myomo e100 Robot and repetitive task specific training, Repetitive task specific training (RTP) targeting the affected arm, Myomo e100 neurorobotic brace
Device · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
35 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Sep 11, 2026, 9:11 AM EDT
Not listed Not applicable Interventional

Evaluation of the Effectiveness and Safety of Keeogo™ Dermoskeleton in Subjects With Mobility Impairments Due to Stroke

NCT03986320
View directory record Official record
Conditions
Stroke, Ischemic, Stroke Hemorrhagic, Stroke, Hemiparesis, Cerebral Vascular Accident
Interventions
Keeogo™ Dermoskeleton
Device
Lead sponsor
B-Temia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 11, 2026, 9:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exploring Accessible Beauty for Individuals With Upper Extremity Deficits

NCT05945784
View directory record Official record
Conditions
Stroke, Ischemic, Stroke Hemorrhagic, Stroke (CVA) or TIA, Stroke, Acute, Traumatic Brain Injury, SCI - Spinal Cord Injury, Ehlers-Danlos Syndromes (EDS), Lupus Erythematosus, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Amyotrophic Lateral Sclerosis, Graves Disease, Muscular Dystrophies
Interventions
Use of Rare Beauty makeup products
Other
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 11, 2026, 9:11 AM EDT
Not listed Not applicable Interventional

The Use of Electromagnetic Field (EMF) Treatment in Chronic Spinal Cord Injury (SCI) Patients

NCT04050696
View directory record Official record
Conditions
Incomplete Spinal Cord Injury
Interventions
BQ 1.2
Device
Lead sponsor
BrainQ Technologies Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Miami, Florida • West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

NCT01064414
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Concord, California • Fountain Valley, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 2 Interventional

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

NCT04822883
View directory record Official record
Conditions
Cognitive Impairment, Schizophrenia
Interventions
RL-007, RL-007 Matching Placebo
Drug
Lead sponsor
Recognify Life Sciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Not applicable Interventional

Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment

NCT04067622
View directory record Official record
Conditions
Acute Respiratory Failure, Encephalopathy, ARDS, Sepsis, Critical Illness
Interventions
Exersides
Device
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
San Diego, California • Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03917472
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Brolucizumab, Aflibercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control

NCT03242018
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
34
States / cities
Guntersville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Not applicable Interventional Results available

Can rTMS Enhance Somatosensory Recovery After Stroke?

NCT02811913
View directory record Official record
Conditions
Stroke
Interventions
repetitive transcranial magnetic stimulation (rTMS), peripheral sensory stimulation
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Not applicable Interventional

Feasibility of Pediatric CIMT by Televideo

NCT05303883
View directory record Official record
Conditions
Hemiplegic Cerebral Palsy
Interventions
Pediatric Constrained Induced Movement Therapy
Other
Lead sponsor
Ohio State University
Other
Eligibility
1 Year to 10 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Columbus, Ohio • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 11, 2026, 9:11 AM EDT
Terminated Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04611152
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
48
States / cities
La Jolla, California • Redlands, California • Santa Maria, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 11, 2026, 9:11 AM EDT
Not yet recruiting Not applicable Interventional

Optimal Targeted High-definition Transcranial Direct Current Stimulation for Reducing Post-stroke Upper Limb Motor Impairments

NCT07599774
View directory record Official record
Conditions
Hemiparetic Stroke
Interventions
High-definition transcranial direct stimulation: sham, High-definition transcranial direct stimulation: optimal, Modified constraint-induced movement therapy
Device · Behavioral
Lead sponsor
Carle Foundation Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

NCT03436199
View directory record Official record
Conditions
Walking Impairment, Multiple Sclerosis
Interventions
ADS-5102, 137 mg, ADS-5102, 274 mg, Placebo
Drug · Other
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
78
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Sep 11, 2026, 9:11 AM EDT
Terminated Not applicable Interventional

Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer

NCT02370264
View directory record Official record
Conditions
Musculoskeletal Complication, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Therapy-Related Toxicity
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Medical Chart Review
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

NCT02055118
View directory record Official record
Conditions
Hunter Syndrome
Interventions
idursulfase-IT, No IT treatment
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
Up to 18 Years · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 11, 2026, 9:11 AM EDT
Recruiting Phase 1 Interventional

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

NCT06825559
View directory record Official record
Conditions
Cholestatic Liver Disease
Interventions
Saroglitazar Magnesium 1 mg
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment

NCT01316055
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Dalfampridine-ER
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 11, 2026, 9:11 AM EDT
Recruiting Not applicable Interventional

Physical Therapy for Montana Children With NMD Using Hippotherapy and the Equine Environment

NCT06887647
View directory record Official record
Conditions
Neuromotor Impairments
Interventions
Physical Therapy Using Hippotherapy and the Equine Environment, Standard Play-Based Physical Therapy
Other
Lead sponsor
University of Montana
Other
Eligibility
6 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 4 Interventional Results available

Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment

NCT02788474
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
nintedanib, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Jasper, Alabama • Danbury, Connecticut • Clearwater, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 11, 2026, 9:11 AM EDT